Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) regularly issues news on its RNA interference (RNAi) therapeutics, commercial performance, pipeline progress, and corporate developments. As a company that has led the RNAi field from discovery to approved medicines, its announcements often highlight data from pivotal trials, regulatory milestones, and updates on marketed products such as AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
Investors following ALNY news can expect detailed coverage of clinical results across multiple therapeutic areas, including transthyretin‑mediated amyloidosis (ATTR), hypertension, bleeding disorders, neurological diseases, and metabolic conditions. Recent releases have described post hoc analyses from the HELIOS‑B Phase 3 study of AMVUTTRA in ATTR‑CM and hATTR‑PN, showing effects on gastrointestinal events, cardiac structure and function, and renal outcomes, as well as broader safety and efficacy profiles.
Alnylam’s news flow also includes financial and strategic updates. The company reports quarterly and annual net product revenues, trends in its TTR and rare disease franchises, and guidance associated with frameworks such as its Alnylam P5x25 and Alnylam 2030 strategies. Filings and press releases have discussed convertible senior notes, a revolving credit facility, and partial repurchases of outstanding debt, providing context on capital structure and liquidity.
Operational and manufacturing developments are another key news theme. Alnylam has announced expansion of its Norton, Massachusetts siRNA manufacturing facility and the integration of its siRELIS enzymatic ligation platform, which has been accepted into the FDA’s Emerging Technology Program. Corporate governance items, such as changes to the Board of Directors and executive responsibilities, are also disclosed. For anyone tracking ALNY, this news stream offers insight into clinical milestones, commercial execution, manufacturing scale‑up, and strategic direction in RNAi therapeutics.
Alnylam (NASDAQ: ALNY) will present new analyses of vutrisiran in ATTR-CM at Heart Failure 2026 (May 9–12, 2026) in Barcelona. Presentations include HELIOS-B subgroup pharmacodynamics, pooled safety analyses on vitamin A outcomes, and the design of the global DemonsTTRate observational study.
Alnylam (Nasdaq: ALNY) reported Q1 2026 consolidated total revenues of $1.167 billion and total net product revenues of $1.036 billion (121% growth vs Q1 2025). Total TTR net product revenues were $910 million (153% growth). The company reiterated 2026 guidance of $4.9–$5.3 billion total net product revenues.
Cash and marketable securities were $3.0 billion as of March 31, 2026; multiple late‑stage clinical readouts are expected in H2 2026.
Alnylam (Nasdaq: ALNY) will report first quarter 2026 financial results for the period ended March 31, 2026 on Thursday, April 30, 2026, before U.S. markets open. Management will discuss Q1 results and expectations on a conference call at 8:30 am ET.
A live audio webcast will be available on the company Investors website and an archived webcast will post approximately two hours after the event.
Alnylam (Nasdaq: ALNY) presented ACC.26 data showing vutrisiran improves quality of life and clinical outcomes in ATTR-CM and real-world adherence is high. Vutrisiran reduced progression to advanced disease (8.0% vs 10.7% placebo) and lowered risk of death/CV events by up to 77% in subgroups. A pooled Phase 2 analysis found zilebesiran’s safety profile acceptable, supporting the ongoing ZENITH Phase 3 CVOT initiated September 2025.
Alnylam (Nasdaq: ALNY) announced partnerships to advance earlier diagnosis and coordinated care for transthyretin-mediated cardiomyopathy (ATTR-CM).
The company will partner with Viz.ai to deploy an FDA-cleared echocardiography AI (Us2.ai) and launch the multi-system AWARE study at five pilot health systems later this year. Alnylam also supports a three-year American Heart Association learning collaborative with a 10-site cohort. A webinar is scheduled today at 9:30 am ET, with an archived webcast available ~two hours after the event.
Alnylam (Nasdaq: ALNY) will webcast a TTR Investor Webinar on Tuesday, March 24, 2026 at 9:30 AM ET. The event marks one year since U.S. FDA approval of AMVUTTRA for ATTR-CM and will feature senior commercial and medical leaders. A replay will be available within 48 hours.
Alnylam (Nasdaq: ALNY) will present a company overview at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET. A live audio webcast will be available on the company investor site and a replay will be posted within 48 hours.
Alnylam (Nasdaq: ALNY) reported Q4 2025 global net product revenues of $995 million and full‑year 2025 net product revenues of $2,987 million, representing 121% and 81% growth versus 2024. The company achieved GAAP and non‑GAAP profitability for 2025 and outlined its Alnylam 2030 five‑year strategy and 2026 pipeline goals.
Key drivers included the U.S. approval and launch of AMVUTTRA for ATTR‑CM, strong royalties from Leqvio sales, a planned $250 million investment in a proprietary enzymatic‑ligation manufacturing facility, and multiple upcoming clinical readouts in 2026.
Alnylam (Nasdaq: ALNY) will report fourth quarter and full-year 2025 financial results on Thursday, February 12, 2026, before U.S. markets open. Management will host a conference call and live audio webcast at 8:30 AM ET to discuss results and expectations. An archived webcast will be posted about two hours after the event.
Alnylam (Nasdaq: ALNY) reported preliminary full year 2025 net product revenues of $2,987M (81% growth vs. 2024), driven by preliminary total TTR revenues of $2,487M (103% growth). The company provided 2026 combined net product revenue guidance of $4,900M–$5,300M (midpoint ~71% growth), led by Total TTR guidance of $4,400M–$4,700M. New five-year strategy Alnylam 2030 targets TTR leadership, launch of nucresiran in polyneuropathy by 2028 and cardiomyopathy by 2030, 2+ new transformative medicines, expansion to 10 tissue types and >40 programs, ~30% of revenues invested in non-GAAP R&D, 25%+ total revenue CAGR to 2030 and ~30% non-GAAP operating margin.